Exportación Completada — 

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies. In cohort A of the phase 2 MM‐014 trial, we examined the safety and efficacy of pomalidomide plus low‐dose dexamethasone immediately...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Siegel, David S., Schiller, Gary J., Song, Kevin W., Agajanian, Richy, Stockerl‐Goldstein, Keith, Kaya, Hakan, Sebag, Michael, Samaras, Christy, Malek, Ehsan, Talamo, Giampaolo, Seet, Christopher S., Mouro, Jorge, Pierceall, William E., Zafar, Faiza, Chung, Weiyuan, Srinivasan, Shankar, Agarwal, Amit, Bahlis, Nizar J.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Haematological Malignancy‐Clinical
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027539/
https://ncbi.nlm.nih.gov/pubmed/31588567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16213
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares